Phase 1 Dose Escalation Study for VIP236 in Patients with Advanced Cancer
NCT05712889
DESCRIPTION OF STUDY
This is a Phase 1 dose-escalation study. The purpose of the study is to determine the safety, tolerability, and maximum tolerated dose of VIP236 in patients with advanced solid tumor cancer.
ELIGIBILITY
- Age: 18+
- Sex: Both
- Status: Recruiting